A detailed history of Susquehanna International Group, LLP transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Susquehanna International Group, LLP holds 46,048 shares of VRTX stock, worth $18.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
46,048
Previous 79,578 42.13%
Holding current value
$18.8 Million
Previous $37.3 Million 42.58%
% of portfolio
0.0%
Previous 0.01%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$460.0 - $505.78 $15.4 Million - $17 Million
-33,530 Reduced 42.13%
46,048 $21.4 Million
Q2 2024

Aug 15, 2024

SELL
$392.81 - $485.53 $6.05 Million - $7.48 Million
-15,402 Reduced 16.22%
79,578 $37.3 Million
Q1 2024

May 07, 2024

SELL
$407.69 - $446.08 $12.6 Million - $13.8 Million
-30,904 Reduced 24.55%
94,980 $39.7 Million
Q4 2023

Feb 14, 2024

SELL
$343.0 - $410.68 $25.2 Million - $30.1 Million
-73,360 Reduced 36.82%
125,884 $51.2 Million
Q3 2023

Nov 14, 2023

BUY
$338.18 - $362.46 $8.44 Million - $9.05 Million
24,958 Added 14.32%
199,244 $69.3 Million
Q2 2023

Aug 11, 2023

SELL
$314.42 - $351.91 $22.3 Million - $25 Million
-71,067 Reduced 28.97%
174,286 $61.3 Million
Q1 2023

May 16, 2023

SELL
$283.23 - $323.1 $9.53 Million - $10.9 Million
-33,648 Reduced 12.06%
245,353 $77.3 Million
Q4 2022

Feb 14, 2023

BUY
$285.76 - $321.48 $66.5 Million - $74.8 Million
232,658 Added 502.03%
279,001 $80.6 Million
Q3 2022

Nov 14, 2022

SELL
$273.83 - $305.53 $16.9 Million - $18.9 Million
-61,778 Reduced 57.14%
46,343 $13.4 Million
Q2 2022

Aug 15, 2022

BUY
$234.96 - $292.55 $1.24 Million - $1.54 Million
5,268 Added 5.12%
108,121 $30.5 Million
Q1 2022

May 16, 2022

SELL
$221.42 - $260.97 $51.7 Million - $60.9 Million
-233,472 Reduced 69.42%
102,853 $26.8 Million
Q4 2021

Feb 14, 2022

SELL
$177.01 - $223.45 $37.9 Million - $47.8 Million
-213,904 Reduced 38.88%
336,325 $73.9 Million
Q3 2021

Nov 15, 2021

BUY
$181.39 - $202.99 $8.47 Million - $9.48 Million
46,682 Added 9.27%
550,229 $99.8 Million
Q2 2021

Aug 11, 2021

BUY
$187.49 - $221.1 $877,640 - $1.03 Million
4,681 Added 0.94%
503,547 $102 Million
Q1 2021

May 17, 2021

BUY
$207.02 - $241.31 $51.2 Million - $59.6 Million
247,146 Added 98.18%
498,866 $107 Million
Q4 2020

Feb 16, 2021

BUY
$207.01 - $276.09 $48.1 Million - $64.1 Million
232,147 Added 1186.06%
251,720 $59.5 Million
Q3 2020

Nov 16, 2020

SELL
$255.65 - $303.1 $32.9 Million - $39 Million
-128,739 Reduced 86.8%
19,573 $5.33 Million
Q2 2020

Aug 14, 2020

BUY
$225.48 - $295.8 $17.6 Million - $23.1 Million
77,971 Added 110.85%
148,312 $43.1 Million
Q1 2020

May 15, 2020

SELL
$199.77 - $247.81 $9.46 Million - $11.7 Million
-47,364 Reduced 40.24%
70,341 $16.7 Million
Q4 2019

Feb 14, 2020

BUY
$166.71 - $223.91 $19.3 Million - $25.9 Million
115,618 Added 5539.91%
117,705 $25.8 Million
Q3 2019

Nov 14, 2019

SELL
$166.23 - $187.09 $2.06 Million - $2.32 Million
-12,383 Reduced 85.58%
2,087 $354,000
Q2 2019

Aug 16, 2019

BUY
$164.61 - $190.37 $1.95 Million - $2.26 Million
11,863 Added 455.04%
14,470 $2.65 Million
Q1 2019

May 15, 2019

SELL
$163.73 - $194.7 $3.44 Million - $4.09 Million
-20,981 Reduced 88.95%
2,607 $480,000
Q2 2018

Aug 14, 2018

BUY
$145.72 - $169.96 $2.82 Million - $3.29 Million
19,340 Added 455.27%
23,588 $4.01 Million
Q1 2018

May 15, 2018

SELL
$151.6 - $177.13 $18,343 - $21,432
-121 Reduced 2.77%
4,248 $692,000
Q4 2017

Feb 14, 2018

SELL
$137.28 - $155.55 $718,660 - $814,304
-5,235 Reduced 54.51%
4,369 $655,000
Q3 2017

Nov 14, 2017

BUY
$148.13 - $162.24 $1.42 Million - $1.56 Million
9,604
9,604 $1.46 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.